Synthesis of a functional chloramphenicol acetyltransferase gene with changed codon composition

<p><b>Copyright information:</b></p><p>Taken from "Removal of mismatched bases from synthetic genes by enzymatic mismatch cleavage"</p><p>Nucleic Acids Research 2005;33(6):e58-e58.</p><p>Published online 30 Mar 2005</p><p>PMCID:PMC1072809.</p><p>© The Author 2005. Published by Oxford University Press. All rights reserved</p> The ratio of ‘active clones’ to ‘analyzed clones’ as described in the text is shown for different gene synthesis methods with or without an EMC step. A significant increase of can be observed only in the cases where EMC is combined with an exonuclease activity present in the reaction or in the later amplification reaction. Prolonged incubation with endonuclease V results in no detectable product after the amplification steps (ss, single-stranded synthesis, ds, double-stranded synthesis; VII, T4 endonuclease VII; V, endonuclease V; T, Taq DNA polymerase; and Vn, Vent DNA polymerase)

LDA classifications for the cross-validation between Bonn and Marburg.

<p>Table 3 shows cross tables of the estimated vs. true AD and HC participants. Estimates for the LDA were gathered from one site and applied to classify the participants from the other site (LDA: Bonn to Marburg and LDA: Marburg to Bonn).</p><p>LDA classifications for the cross-validation between Bonn and Marburg.</p

LDA^a classifications for the leave-one-out cross-validations.

<p>Table 2 shows cross tables of the estimated vs. true AD and HC participants from the two sites (Marburg and Bonn). Estimations were drawn from the outcome of a leave-one-out cross-validation of the LDA model.</p><p>Abbreviations</p><p>^a LDA Linear discriminant analysis</p><p>^b AD Alzheimer’s disease</p><p>^c HC healthy control</p><p>LDA<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132227#t002fn003" target="_blank">^a</a> classifications for the leave-one-out cross-validations.</p

Clinical characteristics of patients with Alzheimer’s disease and healthy controls.

<p>All values are arithmetic means with standard deviations in parentheses, except for sex, smoker status, drug treatment, and cerebrospinal fluid taken.</p><p>Abbreviations</p><p>^a AD Alzheimer’s disease</p><p>^b PD Parkinson’s disease</p><p>^c HC healthy control</p><p>^d n/a not applicable</p><p>^e MMSE mini-mental state examination.</p><p>^f pTau hyperphosphorylated tau protein</p><p>^g Aβ₄₂ amyloid-beta 1–42</p><p>^h Aβ₄₀ amyloid-beta 1–40</p><p>ⁱ n.s. not significant.</p><p>Clinical characteristics of patients with Alzheimer’s disease and healthy controls.</p

Linear discriminant analysis.

<p>In Fig 1, we tested whether differentiating among patients with two neurodegenerative disorders and healthy controls is possible using the eNose. Linear discriminant analysis (LDA) was used to distinguish among groups. Repeated measurements were evaluated using median values and normalised to a range of 0 to 1. LD = linear discriminant, ad = Alzheimer's disease, pd = Parkinson's disease, hc = healthy control.</p

Study Design.

<p>Study Design.</p

RLS-associated SNPs representing <i>cis</i>-eQTLs in peripheral blood.

<p>A total of 23 <i>cis</i>-eQTLs were found in both KORA F4 and SHIP-TREND at p_nominal<1×10⁻³. SNPs which were carried into the replication phase are printed in bold. NS = not significant.</p